 |
||||||
 |
||||||
 |
||||||
 |
||||||
 |
||||||
 |
||||||
 |
||||||
 |
||||||
 |
||||||
|
DepoDur: Safety Profile14
Safety and tolerability in clinical studies
 |
The majority of adverse events were typical of opioids | |
|
The most common adverse events (greater than 10%) were decreased oxygen saturation, hypotension, urinary retention, vomiting, constipation, nausea, pruritus, pyrexia, anemia, headache, and dizziness | |
|
As with all opioids, the most serious side effect of morphine sulfate is respiratory depression, especially in elderly and debilitated patients, and in those with compromised respiratory function | |
|
Due to the extended release of morphine, patients receiving DepoDur should be monitored for 48 hours | |
|
Overall incidence of respiratory depression was dose related—10 mg (0.7%), 15 mg (5%)13 | |
DepoDur is a Schedule II controlled substance and is subject to abuse and diversion. |
||
DepoDur: Monitoring
Monitoring following opioid administration
The American Society of Anesthesiologists (ASA) recommends that all patients receiving neuraxial opioids be monitored for adequacy of ventilation, oxygenation, and level of consciousness15
| Type of Administration |
Duration of Monitoring | Hours 1-12 |
Hours 12-24 |
After 24 Hours |
| DepoDur | A minimum of 48 hours | At least 1x per hour | At least 1x every 2 hours |
At least 1x every 4 hours |
| Single-Injection Hydrophilic Opioid (not extended-release epidural morphine) |
A minimum of 24 hours | At least 1x per hour | At least 1x every 2 hours |
Monitoring based on patient’s clinical condition and concurrent medications |
| Continuous Infusion or Patient-Controlled Epidural Analgesia |
For duration of infusion and post- infusion based on patient’s clinical condition |
At least 1x per hour | At least 1x every 2 hours |
At least 1x every 4 hours |
Please see important safety information and full Prescribing Information.
 |
|||
|
|||
Terms and Conditions Privacy Policy Contact Us About EKR Therapeutics